The BA.3.2 variant, commonly referred to as the Cicada variant, is a descendant of the BA.3 subvariant of Omicron that emerged in 2022. It was first identified in South Africa in November 2024 and has since been detected in over 20 countries, including 25 states in the United States. With approximately 70 to 75 mutations in its spike protein, the Cicada variant has raised concerns among health officials and the public alike.

Initial reports indicate that common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those of previous COVID-19 strains, particularly the Omicron variants.

Despite the presence of these symptoms, current evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier variants. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” Most cases appear to be mild to moderate, resembling flu-like illness, especially among vaccinated individuals.

Health experts emphasize that the current COVID-19 vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. However, there are concerns regarding the variant’s multiple mutations, which may impact vaccine effectiveness. Observers note that while the vaccines may not be as effective against the Cicada variant, they still offer significant protection against severe outcomes.

The Cicada variant primarily spreads through respiratory droplets and close contact in crowded or poorly ventilated spaces, similar to other COVID-19 variants. Health authorities are actively monitoring its rise, particularly in the United States, where cases are currently increasing.

Health experts recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the spread of the virus. As the situation develops, health officials continue to assess the variant’s impact and provide guidance to the public.

In summary, the symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains, and there is no strong evidence suggesting increased severity of illness caused by this variant. Most cases remain mild and can be managed at home with rest and hydration. Details remain unconfirmed as health authorities continue to gather data on this emerging variant.

The post Cicada COVID Variant Symptoms appeared first on newscri.

As of March 2026, the cicada COVID variant BA.3.2 has been detected in at least 25 states across the United States, prompting significant public health concerns. This heavily mutated strain of SARS-CoV-2 may evade immunity from both vaccines and prior infections, which could complicate efforts to control the pandemic.

BA.3.2 was first identified in November 2024 in South Africa and has since spread to at least 23 countries. It is characterized by 70 to 75 mutations in its spike protein, which may reduce the effectiveness of existing vaccines against infection, although they are still expected to provide protection against severe disease.

In the U.S., BA.3.2 was first detected in June 2025 in a traveler returning from the Netherlands. Since then, it has rapidly proliferated, accounting for approximately 30% of cases in Denmark, Germany, and the Netherlands. Nationwide, about 3.7% of sewage samples have shown the presence of BA.3.2, indicating its widespread circulation.

Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues. Experts emphasize the importance of vaccination, stating that it will still help limit cases despite the variant’s mutations. Andrew Pekosz, Ph.D., noted, “It has a lot of mutations that may cause it to look different to your immune system.”

Despite these concerns, health officials, including Dr. Adolfo García-Sastre, have indicated that there is currently no evidence that BA.3.2 is causing more severe disease or hospitalizations compared to previous strains. This variant has been classified as a ‘variant under monitoring’ by the World Health Organization since December 2025.

Details remain unconfirmed regarding the exact reasons for the resurgence of BA.3.2, and the long-term impact of this variant on public health remains uncertain. As the situation evolves, continued surveillance and research will be crucial in understanding the implications of this emerging strain.

The post Cicada COVID Variant BA.3.2 Raises Concerns in the United States appeared first on newscri.

A meningococcal meningitis outbreak in Canterbury, Kent, raises the question: how serious is the situation among the student population? The outbreak has resulted in two fatalities and 20 reported cases of meningococcal disease, prompting urgent public health measures.

The outbreak is linked to Club Chemistry, a nightclub in Canterbury, where individuals attended between March 5 and 7. Of the confirmed cases, six have been identified as group B meningococcal disease, which is particularly concerning given the rapid spread.

In response, the UK Health Security Agency (UKHSA) is coordinating a national response, describing the outbreak as a public health emergency of unusual speed and scale. A mass vaccination program targeting 5,000 students at the University of Kent is being implemented, alongside the prescription of antibiotics to approximately 2,500 individuals who were in close contact with confirmed cases.

Wes Streeting, a health official, expressed concern about the unprecedented pace of the outbreak, stating, “What’s worried us about the Canterbury outbreak is the pace and extent of the spread of the disease — that is unprecedented.” This sentiment is echoed by Trish Mannes, who emphasized the importance of vaccination as a critical intervention to protect individuals and halt the outbreak.

Symptoms of meningococcal disease include fever, severe headache, and a stiff neck. Early treatment is crucial, as highlighted by a parent, Candice Skinner, who described her daughter’s rapid decline from what initially seemed like flu symptoms.

As of now, there are 11 notifications under investigation by the UKHSA, with nine cases confirmed by laboratory tests. The exact origin of the outbreak remains under investigation, and details remain unconfirmed regarding the potential for the outbreak to spread beyond British borders.

The situation continues to evolve, with health authorities urging students and residents to remain vigilant and seek medical attention if symptoms arise.

The post Meningococcal Meningitis Outbreak in Canterbury Raises Concerns appeared first on newscri.

The recent launch of a nationwide HPV vaccination program in India is expected to significantly reduce the burden of cervical cancer, which is the second-most prevalent form of cancer among women in the country. Cervical cancer is primarily caused by the human papillomavirus (HPV), and the vaccine can prevent nearly 90% of these cases. This initiative, which began on February 28, 2026, aims to vaccinate 14-year-old girls across the nation, providing them with a crucial tool in the fight against this disease.

The vaccination program is notable for its accessibility, as the HPV vaccine is administered free of cost at government health facilities. Vaccination is voluntary and requires parental consent, ensuring that families have a choice in their healthcare decisions. Dr. Chandini, a health expert, emphasized the importance of the vaccine, stating, “The HPV vaccine is safe and can prevent nearly 90 percent of cervical cancer, which is the second most common cancer among women in India.” This statement underscores the critical role the vaccine will play in protecting young girls from a disease that has a significant impact on women’s health.

India currently has three approved HPV vaccines: Cervarix®, Gardasil®, and Gardasil-9®. Additionally, Cervavac®, developed by the Serum Institute of India, was approved by the Drug Controller General of India in July 2022. The ongoing vaccination campaign will utilize the single-dose Gardasil-4 vaccine, which is considered cost-effective at a threshold of 30% of GDP per capita. This cost-effectiveness is crucial for a country where healthcare resources can be limited.

With India accounting for over 65% of the regional burden of cervical cancer, the vaccination program is a vital step towards reducing these statistics. The campaign is expected to last for 90 days, during which health officials will work to ensure that as many eligible girls as possible receive the vaccine. The initiative is supported by various organizations, including the World Health Organization and Gavi, which aim to strengthen preventive healthcare measures in the country.

The introduction of HPV vaccines in India dates back to 2008, with state governments in Sikkim and Punjab launching their own vaccination programs in 2016. However, the current nationwide effort marks a significant escalation in the commitment to combat cervical cancer through vaccination. The program’s success will depend on public awareness and participation, as well as the effective distribution of vaccines across diverse regions.

As the vaccination campaign progresses, health officials will monitor its impact on cervical cancer rates and overall public health. The hope is that this initiative will not only protect young girls from cervical cancer but also pave the way for a broader understanding of preventive healthcare in India. The ongoing nationwide HPV vaccination program will contribute to reducing the burden of cervical cancer and strengthening preventive healthcare in India.

Details remain unconfirmed regarding the long-term effects of this vaccination campaign on cervical cancer rates, but the initial response from the public and health professionals has been positive. The success of this program could serve as a model for other countries facing similar health challenges, highlighting the importance of vaccination in public health strategies.

The post Hpv vaccine: India Launches Nationwide Campaign to Combat Cervical Cancer appeared first on newscri.

The HPV vaccination programme, launched recently, aims to drastically reduce the incidence of cervical cancer in the country. With the Human Papillomavirus (HPV) identified as the leading cause of this type of cancer, the initiative is crucial for public health. The World Health Organization recommends the HPV vaccine for girls aged 9–14 years, aligning with India’s focus on vaccinating adolescent girls to curb future cases of cervical cancer.

In a promising start, India’s HPV vaccination campaign has already vaccinated nearly 3 lakh girls aged 14 within just two weeks of its launch. This rapid uptake highlights the community’s response to the health initiative and the potential for significant impact on public health outcomes. The vaccines, including Gardasil® and the indigenous Cervavac®, are designed to protect against various strains of HPV, including those most commonly associated with cervical cancer.

Gardasil® is known for its efficacy in preventing HPV infection and subsequent cervical cancer, while Cervavac®, which received approval from the Drug Controller General of India in July 2022, represents a significant advancement in local vaccine development. The introduction of Cervavac® is particularly noteworthy as it adds to the options available for vaccination, potentially increasing coverage and accessibility.

Dr (Brig.) Rakesh Gupta emphasized the importance of accessibility in vaccination efforts, stating, “The idea is to create a dedicated space where vaccination services are available throughout the week without disruption.” This approach aims to ensure that girls can receive their vaccinations conveniently, thereby enhancing participation in the program.

HPV vaccines were first introduced in India in 2008, with state governments launching various programs in 2016. The current initiative builds on this foundation, aiming to improve public health infrastructure and raise awareness about the importance of vaccination in preventing cervical cancer. A single dose of the HPV vaccine has been shown to provide durable immunity for up to 18 years, making it a long-term solution for HPV-related health issues.

Looking ahead, the Indian government, in collaboration with organizations like Gavi and the World Health Organization, is expected to continue its efforts to expand the HPV vaccination program. The policy highlights for cervical cancer vaccination drives are set for 2024–25, indicating a long-term commitment to combating this preventable disease.

As the vaccination campaign progresses, it is crucial to monitor its impact on cervical cancer rates in the coming years. The initial success in vaccinating a significant number of girls is a positive sign, but sustained efforts will be necessary to achieve the program’s goals and ensure that the burden of cervical cancer is significantly reduced in India.

The post HPV Vaccination Program Aims to Reduce Cervical Cancer in India appeared first on newscri.

A free HPV vaccination drive was launched at Bharath Cancer Hospital in Mysuru, Karnataka, marking a significant step in the fight against cervical cancer. This initiative aims to create awareness about cervical cancer prevention among women, addressing a pressing health concern that affects many in the region.

The program will provide free HPV vaccinations to the first 200 registered beneficiaries, highlighting the urgency and importance of early intervention. Cervical cancer is the second most common cancer among women globally, with India reporting approximately 1.23 lakh new cases each year. The initiative is particularly timely, as around 67,500 women succumb to cervical cancer in India annually.

The HPV vaccine is most effective for individuals aged between 9 to 14 years, making it crucial to target this demographic for vaccination. On February 28, 2026, the Government of India launched a single-shot HPV vaccination program specifically for girls aged 14 years, with a target of achieving 1.15 crore vaccinations each year. This ambitious goal underscores the government’s commitment to combating cervical cancer through preventive measures.

The HPV vaccine has received approval from India’s drug regulator, and the Gates Foundation is involved in the supply procurement of the vaccine in the country. Currently, the vaccine is available at primary health centers, Community Health Centres, District Health Centres, and government hospitals across Mandya district, ensuring accessibility for those in need.

Dr. Nagalakshmi Choudhary expressed pride in inaugurating such a meaningful program, emphasizing the importance of addressing cervical cancer as a major health concern for women. Dr. C.B. Avinash echoed these sentiments, stating that cervical cancer continues to be a significant health issue that requires immediate attention.

The vaccination campaign in Mandya aims to identify all eligible girls within the next month, ensuring that the benefits of the HPV vaccine reach those who need it most. However, Kumara, a health official, noted that misconceptions and confusion about the vaccine among children and parents must be addressed through proper awareness initiatives.

Despite these positive developments, uncertainties remain regarding the effectiveness of the HPV vaccination program in reducing cervical cancer rates in India. Additionally, concerns about the influence of foreign organizations on India’s health policymaking are not fully resolved. Details remain unconfirmed, and stakeholders are keenly observing the program’s progress and its potential impact on public health.

The post HPV Vaccine Initiative Launched in Mysuru, Karnataka appeared first on newscri.